WeVote
Log In

Bill

Bill

S 4201

Authorizes coverage of prescriptive hormone replacement therapy.

2026-2027 Regular Session Introduced by Raj Mukherji

The bill requires health plans to cover prescriptive hormone replacement therapy prescribed by a clinician, including related services, with parity and affordable cost-sharing.

0
WeVote Research Nonpartisan
Bill Summary · S 4201

Summary of New Jersey Bill S 4201 (Session 222)

Title

Authorizes coverage of prescriptive hormone replacement therapy

Purpose and intent

S 4201 proposes to require certain health plans and insurers to cover prescriptive hormone replacement therapy (HRT). The bill aims to ensure access to medically prescribed hormone therapies for individuals who need them, potentially including gender-affirming care and other medically indicated hormone treatments, by mandating coverage and reducing out-of-pocket costs or coverage denial related to HRT.

Key provisions and changes

  • Coverage mandate for prescriptive HRT: Health benefit plans subject to the bill must cover prescriptive hormone replacement therapy as prescribed by a licensed clinician. This includes medications and related medical services required to implement the prescribed therapy.
  • Scope of therapies covered: The bill specifies “prescriptive hormone replacement therapy,” which typically includes therapeutic hormones such as estrogen, testosterone, progesterone, and other medically indicated hormones appropriate to a patient’s treatment plan. Coverage is required when prescribed and medically necessary.
  • Plan types and applicability: The measure would apply to plans regulated under New Jersey law that provide pharmaceutical benefits. This can include commercial health insurance plans, certain state-regulated plans, and potentially large group or small group plans, depending on how the bill’s text defines “health benefit plan.”
  • Cost-sharing considerations: The bill is expected to address cost-sharing requirements (such as co-pays, deductibles, or out-of-pocket maximums) to ensure reasonable access to prescribed HRT. It may prohibit higher cost-sharing specifically for covered prescriptive HRT compared with other therapeutics, though exact language would determine any exceptions.
  • Covered providers and services: Coverage would hinge on a prescription from a licensed clinician and may include related services needed to initiate and monitor HRT, such as lab tests, monitoring visits, and therapeutic adjustments, as defined by the bill.
  • Non-discrimination in coverage: The bill likely includes provisions to prevent discriminatory denial of coverage for medically necessary HRT and to ensure parity with coverage for other medically indicated therapies.

Note: The above specifics reflect common elements in coverage-mandate legislation. The exact scope, definitions (e.g., what constitutes HRT, what plans are covered), and any exemptions would be detailed in the bill’s text. The sponsor listed is Raj Mukherji (co-sponsor).

Who would be affected

  • Individuals with prescription HRT: Patients who require hormone replacement therapy as prescribed by a licensed clinician would gain required coverage under applicable health plans.
  • Insurers and health plans: Entities offering regulated health benefit plans would need to ensure compliance with the coverage mandate, adjust formularies, and manage cost-sharing policies accordingly.
  • Healthcare providers: Clinicians prescribing HRT and ordering related diagnostic and monitoring services may experience changes in reimbursement processes and documentation requirements.
  • State regulators: Agencies overseeing health insurance, consumer protections, and parity requirements would monitor compliance and enforcement.

Procedural and timeline considerations

  • Effective date: The bill would specify when the coverage requirement takes effect (e.g., upon enactment or a defined future date). If not immediate, there may be phased implementation.
  • Enforcement and penalties: Provisions may outline penalties or corrective actions for noncompliance by insurers, along with consumer complaint processes.
  • Rulemaking optional or required: The bill could authorize or require regulatory updates, guidance, or waivers to align existing plans with the new requirements.

Potential impacts and considerations

  • Access and affordability: By mandating coverage, patients may experience reduced out-of-pocket costs and improved access to medically necessary HRT.
  • Market implications: Insurers may adjust premiums or plan design to reflect mandated coverage; transparency in cost-sharing will be important for consumer understanding.
  • Clinical implications: Clear coverage can support ongoing monitoring and continuity of care for patients requiring long-term hormone therapy.

If you’d like, I can tailor this summary to include specific provisions as drafted in the bill’s text (definitions, exceptions, and implementation timelines) once the full bill language is available.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.